---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-221242"
form_type: "8-K"
ticker: "ABOS"
cik: "0001576885"
company_name: "Acumen Pharmaceuticals, Inc."
filed_at: "2022-08-15T23:59:59+00:00"
generated_at: "2026-06-23T23:50:50.750358+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Acumen Q2 net loss $10.2M; cash $209.9M; Phase 1 topline H1 2023; director resigns

## Summary
- Cash, cash equivalents and marketable securities $209.9M as of June 30, 2022; expected runway through 2025.
- Net loss $10.2M for Q2 2022 vs $61.4M in Q2 2021 (2021 incl $57.9M non-cash liability charge).
- R&D expenses $7.3M (up from $2.3M) due to ongoing Phase 1 INTERCEPT-AD trial.
- Phase 1 INTERCEPT-AD topline results expected H1 2023; 15 active sites recruiting.
- Dr. Jeffrey Sevigny resigned from Board effective Aug 12, 2022 due to employment requirements, not disagreement.

## SEC filing metadata
- accession: 0001193125-22-221242
- form_type: 8-K
- ticker: ABOS
- cik: 0001576885
- company_name: Acumen Pharmaceuticals, Inc.
- filed_at: 2022-08-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1576885/000119312522221242/0001193125-22-221242-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1576885/000119312522221242/d254943d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-221242
- JSON: https://secwatch.observer/filing/0001193125-22-221242.json
- Plain text: https://secwatch.observer/filing/0001193125-22-221242.txt

## Key facts
- Executive change
  Jeffrey Sevigny resigned as Director at Acumen Pharmaceuticals, Inc..
  - Action: resigned
  - Role: Director
  source text: On August 12, 2022, Dr. Jeffrey Sevigny notified the Board of Directors of his resignation from the Board of Directors, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1576885/000119312522221242/0001193125-22-221242-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.